OctoRelease is in the process of acquiring its own  Manufacturing License, Ensuring Quality and Regulatory Compliance for Your Clinical Trials

OctoRelease is proud to announce the acquisition of its own manufacturing license from the Dutch Authorities. This significant milestone marks a new era for OctoRelease, positioning the company as a leading provider of comprehensive clinical trial solutions, including both development and manufacturing. With this new license, OctoRelease will have two Qualified Persons (QPs) to certify the manufactured final drug product used in your clinical trials.

Streamlined Regulatory Compliance and Increased Efficiency

Obtaining a manufacturing license is a complex and time-consuming process. By acquiring its own license, OctoRelease streamlines the regulatory and quality compliance process for its clients, saving them valuable time and resources. This streamlined approach allows OctoRelease to focus on the core of its mission: providing high-quality clinical trial services that meet the highest quality standards.

Enhanced Quality Assurance and Patient Safety

With two QPs overseeing the manufacturing process, OctoRelease ensures that every stage of production adheres to strict regulatory guidelines. This commitment to quality is paramount in safeguarding the safety and well-being of participants in clinical trials.

Expanded Capabilities for Clinical Trial Success

By outsourcing manufacturing and release to OctoRelease, clients can introduce their Investigative drug faster in the clinics.